secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHINA PHARMA HOLDINGS, INC. (CPHI)
CIK:        0001106644
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001213900-23-097680
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02
LLM model:  deepseek-v4-flash:cloud@v2

China Pharma acquires COPD drug patent for $1.65M in restricted stock; royalty of 15% net profit
--------------------------------------------------------------------------------

- Subsidiary Helpson enters Technology Transfer Agreement with Tao Liu for a COPD drug combination patent.
- Consideration: 15,000,000 restricted shares at $0.11/share ($1.65M) under Regulation S exemption.
- Helpson to pay 15% of net profit from product sales annually for 10 years if product is profitable.
- Transferor to provide R&D, registration, and technical services in Haikou.
- Shares are unregistered and issued in an offshore transaction to a non-U.S. person.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1106644/000121390023097680/0001213900-23-097680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1106644/000121390023097680/ea190499-8k_chinapharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-097680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer